ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Curcumin for the Prevention of Colon Cancer

This study has been completed.
Information provided by National Cancer Institute (NCI)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Curcumin for the Prevention of Colon Cancer
Official Title  Phase I Pharmacokinetic Trial of Curcuminoids Administered in a Capsule Formulation
Brief Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Curcumin may be effective in preventing the development of colon cancer.

PURPOSE: Phase I trial to determine the dose amount of curcumin that can be tolerated to help in preventing colon cancer in healthy men and women.

Detailed Description

OBJECTIVES:

  • Determine the maximum tolerated dose (MTD) of curcumin as a chemopreventive agent of colon cancer in healthy subjects.
  • Determine if tolerable doses of this agent in uniformly milled formulation capsules are bioavailable in these subjects.
  • Determine the pharmacokinetics of this agent and two metabolites at the MTD and next lower escalated dose in these subjects.

OUTLINE: This is a dose escalation study followed by a pharmacokinetic study.

Patients receive a single oral dose of curcumin followed by a standard fatty meal.

Cohorts of 3-6 patients receive escalating doses of curcumin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicities. Once the MTD is determined, additional patients are accrued to receive curcumin in the pharmacokinetic phase of the study.

Patients are followed at 24, 36, 48, and 72 hours.

PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for the dose escalation phase and then 12 additional patients will be accrued for the pharmacokinetic phase of this study within 3 months.

Study Phase Phase I
Study Type  Interventional
Study Design  Prevention
Primary Outcome Measure 
Secondary Outcome Measure 
Condition  Colorectal Cancer
Intervention  Drug: curcumin
MEDLINE PMIDs
Links Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site
Recruitment Information Fields
Recruitment Status  Completed
Enrollment 
Start Date  December 2001
Completion Date
Eligibility Criteria 

DISEASE CHARACTERISTICS:

  • Healthy men and women age 18 and over

PATIENT CHARACTERISTICS:

Age:

  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified

Hematopoietic:

  • WBC greater than 4,000/mm3
  • Hemoglobin greater than 12 g/dL
  • Platelet count greater than 120,000/mm3

Hepatic:

  • ALT/AST less than 1.5 times upper limit of normal (ULN)
  • Alkaline phosphatase less than 1.5 times ULN
  • Bilirubin less than 1.5 mg/dL

Renal:

  • Creatinine less than 1.7 mg/dL

Other:

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No prior cancer except surgically resected basal cell or squamous cell skin cancer
  • No history of peptic ulcer disease, gastrointestinal bleeding from gastric or duodenal ulcers, or gastrin secreting tumors
  • No history of unreliability or noncompliance (missing pretreatment appointment more than twice)

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • Not specified

Endocrine therapy:

  • At least 14 days since prior steroids

Radiotherapy:

  • Not specified

Surgery:

  • Not specified

Other:

  • At least 14 days since prior curcumin (turmeric) rich foods
  • At least 14 days since prior nonsteroidal antiinflammatory drugs (NSAIDs)
  • No chronic medications (i.e., daily for more than 28 days) except for oral contraceptives
  • No concurrent coumadin or other anticoagulants
Gender Both
Ages 18 Years and older
Accepts Healthy Volunteers No
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00027495
Organization ID CDR0000067916
Secondary IDs †† CCUM-9941, NCI-P00-0144, UMN-9941
Study Sponsor  University of Michigan Cancer Center
Collaborators †† National Cancer Institute (NCI)
Investigators 
Study Chair:     Dean E. Brenner, MD     University of Michigan Cancer Center    
Information Provided By National Cancer Institute (NCI)
Verification Date June 2004
First Received Date  December 7, 2001
Last Updated Date July 23, 2008

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers